Holen Sie sich die Stockscreener-App
1.47
4.55%
-0.07
Handel nachbörslich:
1.50
0.03
+2.04%
Schlusskurs vom Vortag:
$1.54
Offen:
$1.53
24-Stunden-Volumen:
1.17M
Relative Volume:
1.17
Marktkapitalisierung:
$123.55M
Einnahmen:
$20.76M
Nettoeinkommen (Verlust:
$-132.49M
KGV:
-0.5506
EPS:
-2.67
Netto-Cashflow:
$-108.55M
1W Leistung:
-15.52%
1M Leistung:
+13.08%
6M Leistung:
-75.74%
1J Leistung:
-78.38%
1-Tages-Spanne:
$1.45
$1.63
1-Wochen-Bereich:
$1.40
$1.72
52-Wochen-Spanne:
$1.085
$7.66
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Firmenname
C 4 Therapeutics Inc
Sektor
Branche
Telefon
(617) 231-0700
Adresse
490 ARSENAL WAY, WATERTOWN
Vergleichen Sie CCCC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
1.47 | 123.55M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Equal-Weight |
| 2024-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-04-28 | Eingeleitet | Credit Suisse | Underperform |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-10 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-11-23 | Eingeleitet | BofA Securities | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-27 | Eingeleitet | Jefferies | Buy |
Alle ansehen
C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Reports Q1 2025 Financial Results - TipRanks
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
C4 Therapeutics Inc (CCCC) Q1 2025 Earnings: EPS Loss of $0.37 Beats Estimate, Revenue Surges to $7.2 Million - GuruFocus
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eagle-Tribune
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Protara Therapeutics Expands Leadership Team: New CPO Receives 61,500 Equity Awards Amid Growth Push - Stock Titan
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Summit Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) #2 - marketscreener.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40% - simplywall.st
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - TradingView
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Announces Board Member Retirement - Investing.com
C4 Therapeutics Announces Board Member Retirement By Investing.com - Investing.com UK
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Finanzdaten der C 4 Therapeutics Inc-Aktie (CCCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):